## Albert Giralt

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/159780/albert-giralt-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

72	3,305	31	57
papers	citations	h-index	g-index
83 ext. papers	3,963 ext. citations	7.8 avg, IF	4.99 L-index

#	Paper	IF	Citations
72	Meridianins Rescue Cognitive Deficits, Spine Density and Neuroinflammation in the 5xFAD Model of Alzheimer's Disease <i>Frontiers in Pharmacology</i> , <b>2022</b> , 13, 791666	5.6	1
71	The Non-receptor Tyrosine Kinase Pyk2 in Brain Function and Neurological and Psychiatric Diseases. <i>Frontiers in Synaptic Neuroscience</i> , <b>2021</b> , 13, 749001	3.5	0
70	RTP801/REDD1 contributes to neuroinflammation severity and memory impairments in Alzheimer's disease. <i>Cell Death and Disease</i> , <b>2021</b> , 12, 616	9.8	6
69	Comparison of the biological impact of aerosol of e-vapor device with MESH technology and cigarette smoke on human bronchial and alveolar cultures. <i>Toxicology Letters</i> , <b>2021</b> , 337, 98-110	4.4	3
68	Longitudinal evaluation of a novel BChE PET tracer as an early biomarker in the brain of a mouse model for Alzheimer disease. <i>Theranostics</i> , <b>2021</b> , 11, 6542-6559	12.1	4
67	Astrocytic BDNF and TrkB regulate severity and neuronal activity in mouse models of temporal lobe epilepsy. <i>Cell Death and Disease</i> , <b>2020</b> , 11, 411	9.8	12
66	The non-receptor tyrosine kinase Pyk2 modulates acute locomotor effects of cocaine in D1 receptor-expressing neurons of the nucleus accumbens. <i>Scientific Reports</i> , <b>2020</b> , 10, 6619	4.9	3
65	Lack of Helios During Neural Development Induces Adult Schizophrenia-Like Behaviors Associated With Aberrant Levels of the TRIF-Recruiter Protein WDFY1. <i>Frontiers in Cellular Neuroscience</i> , <b>2020</b> , 14, 93	6.1	1
64	Meridianins and Lignarenone B as Potential GSK3[Inhibitors and Inductors of Structural Neuronal Plasticity. <i>Biomolecules</i> , <b>2020</b> , 10,	5.9	9
63	Helios modulates the maturation of a CA1 neuronal subpopulation required for spatial memory formation. <i>Experimental Neurology</i> , <b>2020</b> , 323, 113095	5.7	1
62	Comparison of the basic morphology and function of 3D lung epithelial cultures derived from several donors. <i>Current Research in Toxicology</i> , <b>2020</b> , 1, 56-69	2.7	10
61	Pyk2 in the amygdala modulates chronic stress sequelae via PSD-95-related micro-structural changes. <i>Translational Psychiatry</i> , <b>2019</b> , 9, 3	8.6	8
60	Conditional BDNF Delivery from Astrocytes Rescues Memory Deficits, Spine Density, and Synaptic Properties in the 5xFAD Mouse Model of Alzheimer Disease. <i>Journal of Neuroscience</i> , <b>2019</b> , 39, 2441-24	158 <sup>6</sup>	64
59	PKR knockout in the 5xFAD model of Alzheimer's disease reveals beneficial effects on spatial memory and brain lesions. <i>Aging Cell</i> , <b>2019</b> , 18, e12887	9.9	17
58	Cyclin-Dependent Kinase 5 Dysfunction Contributes to Depressive-like Behaviors in Huntington's Disease by Altering the DARPP-32 Phosphorylation Status in the Nucleus Accumbens. <i>Biological Psychiatry</i> , <b>2019</b> , 86, 196-207	7.9	8
57	Early Downregulation of p75 by Genetic and Pharmacological Approaches Delays the Onset of Motor Deficits and Striatal Dysfunction in Huntington's Disease Mice. <i>Molecular Neurobiology</i> , <b>2019</b> , 56, 935-953	6.2	12
56	CDK4 Regulates Lysosomal Function and mTORC1 Activation to Promote Cancer Cell Survival. <i>Cancer Research</i> , <b>2019</b> , 79, 5245-5259	10.1	19

55	E2F1 promotes hepatic gluconeogenesis and contributes to hyperglycemia during diabetes. <i>Molecular Metabolism</i> , <b>2018</b> , 11, 104-112	8.8	13
54	PTK2B/Pyk2 overexpression improves a mouse model of Alzheimer's disease. <i>Experimental Neurology</i> , <b>2018</b> , 307, 62-73	5.7	23
53	Age-related changes in STriatal-Enriched protein tyrosine Phosphatase levels: Regulation by BDNF. <i>Molecular and Cellular Neurosciences</i> , <b>2018</b> , 86, 41-49	4.8	8
52	P1-092: NEUROPROTECTIVE EFFECTS OF PKR KNOCKOUT IN 5XFAD ALZHEIMER MICE AND NEURON-MICROGLIA CO-CULTURES <b>2018</b> , 14, P306-P306		
51	7,8-dihydroxyflavone ameliorates cognitive and motor deficits in a Huntington's disease mouse model through specific activation of the PLCI pathway. <i>Human Molecular Genetics</i> , <b>2017</b> , 26, 3144-3160	5.6	31
50	Pyk2 modulates hippocampal excitatory synapses and contributes to cognitive deficits in a Huntington's disease model. <i>Nature Communications</i> , <b>2017</b> , 8, 15592	17.4	48
49	The AMPA receptor positive allosteric modulator S 47445 rescues in vivo CA3-CA1 long-term potentiation and structural synaptic changes in old mice. <i>Neuropharmacology</i> , <b>2017</b> , 123, 395-409	5.5	15
48	Helios expression coordinates the development of a subset of striatopallidal medium spiny neurons. <i>Development (Cambridge)</i> , <b>2017</b> , 144, 1566-1577	6.6	11
47	CDK4 Phosphorylates AMPK₽ to Inhibit Its Activity and Repress Fatty Acid Oxidation. <i>Molecular Cell</i> , <b>2017</b> , 68, 336-349.e6	17.6	38
46	[P4 <b>0</b> 36]: THE NOVEL AMPA RECEPTOR POSITIVE ALLOSTERIC MODULATOR S 47445 RESCUES IN VIVO CA3-CA1 LONG-TERM POTENTIATION AND STRUCTURAL SYNAPTIC CHANGES IN MIDDLE-AGED MICE <b>2017</b> , 13, P1270-P1270		
45	E2F1, a Novel Regulator of Metabolism. Frontiers in Endocrinology, 2017, 8, 311	5.7	70
44	E2F1 inhibits circulating cholesterol clearance by regulating Pcsk9 expression in the liver. <i>JCI Insight</i> , <b>2017</b> , 2,	9.9	27
43	Loss of striatal 90-kDa ribosomal S6 kinase (Rsk) is a key factor for motor, synaptic and transcription dysfunction in Huntington's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2016</b> , 1862, 1255-66	6.9	2
42	Prostaglandin E2 EP2 activation reduces memory decline in R6/1 mouse model of Huntington's disease by the induction of BDNF-dependent synaptic plasticity. <i>Neurobiology of Disease</i> , <b>2016</b> , 95, 22-3	4 <sup>7·5</sup>	18
41	E2F1 mediates sustained lipogenesis and contributes to hepatic steatosis. <i>Journal of Clinical Investigation</i> , <b>2016</b> , 126, 137-50	15.9	63
40	CDK4 is an essential insulin effector in adipocytes. <i>Journal of Clinical Investigation</i> , <b>2016</b> , 126, 335-48	15.9	47
39	Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels. <i>Journal of Clinical Investigation</i> , <b>2016</b> , 126, 4319-4330	15.9	43
38	Pyk2 is essential for astrocytes mobility following brain lesion. <i>Glia</i> , <b>2016</b> , 64, 620-34	9	15

37	Acute drug-induced spine changes in the nucleus accumbens are dependent on Eddducin. <i>Neuropharmacology</i> , <b>2016</b> , 110, 333-342	5.5	3
36	Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington's disease by preventing p75NTR up-regulation and astrocyte-mediated inflammation. <i>Human Molecular Genetics</i> , <b>2015</b> , 24, 4958-70	5.6	83
35	A role for Kalirin-7 in corticostriatal synaptic dysfunction in Huntington's disease. <i>Human Molecular Genetics</i> , <b>2015</b> , 24, 7265-85	5.6	26
34	Cryostat Slice Irregularities May Introduce Bias in Tissue Thickness Estimation: Relevance for Cell Counting Methods. <i>Microscopy and Microanalysis</i> , <b>2015</b> , 21, 893-901	0.5	1
33	DARPP-32 interaction with adducin may mediate rapid environmental effects on striatal neurons. <i>Nature Communications</i> , <b>2015</b> , 6, 10099	17.4	27
32	Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats. <i>Neurobiology of Disease</i> , <b>2014</b> , 64, 36-47	7.5	10
31	B22 Normalisation Of Aberrant P75NTR Levels Prevents Hippocampal Synaptic And Cognitive Deficits And Ameliorates Cortico-striatal Dysfunction In Huntington Disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2014</b> , 85, A16-A17	5.5	
30	M15 Fingolimod (FTY720) Enhances Hippocampal Synaptic Plasticity and Memory in Huntington Disease by Preventing P75NTR/TRKB Imbalance. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2014</b> , 85, A99-A99	5.5	
29	Prostaglandin E2 EP1 receptor antagonist improves motor deficits and rescues memory decline in R6/1 mouse model of Huntington's disease. <i>Molecular Neurobiology</i> , <b>2014</b> , 49, 784-95	6.2	22
28	Neurotrophin receptor p75(NTR) mediates Huntington's disease-associated synaptic and memory dysfunction. <i>Journal of Clinical Investigation</i> , <b>2014</b> , 124, 4411-28	15.9	71
27	Differential neuroprotective effects of 5'-deoxy-5'-methylthioadenosine. <i>PLoS ONE</i> , <b>2014</b> , 9, e90671	3.7	11
26	Suppressing aberrant GluN3A expression rescues synaptic and behavioral impairments in Huntington's disease models. <i>Nature Medicine</i> , <b>2013</b> , 19, 1030-8	50.5	79
25	Neurobehavioral characterization of Endonuclease G knockout mice reveals a new putative molecular player in the regulation of anxiety. <i>Experimental Neurology</i> , <b>2013</b> , 247, 122-9	5.7	2
24	PDE10 inhibition increases GluA1 and CREB phosphorylation and improves spatial and recognition memories in a Huntington's disease mouse model. <i>Hippocampus</i> , <b>2013</b> , 23, 684-95	3.5	56
23	Imbalance of p75(NTR)/TrkB protein expression in Huntington's disease: implication for neuroprotective therapies. <i>Cell Death and Disease</i> , <b>2013</b> , 4, e595	9.8	63
22	Regulation of hippocampal cGMP levels as a candidate to treat cognitive deficits in Huntington's disease. <i>PLoS ONE</i> , <b>2013</b> , 8, e73664	3.7	47
21	Age-dependent decline of motor neocortex but not hippocampal performance in heterozygous BDNF mice correlates with a decrease of cortical PSD-95 but an increase of hippocampal TrkB levels. <i>Experimental Neurology</i> , <b>2012</b> , 237, 335-45	5.7	21
20	SIRT3, a pivotal actor in mitochondrial functions: metabolism, cell death and aging. <i>Biochemical Journal</i> , <b>2012</b> , 444, 1-10	3.8	178

## (2007-2012)

19	Activation of Elk-1 participates as a neuroprotective compensatory mechanism in models of Huntington's disease. <i>Journal of Neurochemistry</i> , <b>2012</b> , 121, 639-48	6	24
18	Cognitive Dysfunction in Huntington's Disease: Humans, Mouse Models and Molecular Mechanisms. Journal of Huntingtons Disease, <b>2012</b> , 1, 155-73	1.9	45
17	Long-term memory deficits in Huntington's disease are associated with reduced CBP histone acetylase activity. <i>Human Molecular Genetics</i> , <b>2012</b> , 21, 1203-16	5.6	109
16	Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. <i>EMBO Molecular Medicine</i> , <b>2012</b> , 4, 380-95	12	431
15	Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicity. <i>Journal of Neuroscience</i> , <b>2011</b> , 31, 8150-62	6.6	55
14	Caveolin-1 deficiency causes cholesterol-dependent mitochondrial dysfunction and apoptotic susceptibility. <i>Current Biology</i> , <b>2011</b> , 21, 681-6	6.3	143
13	Conditional BDNF release under pathological conditions improves Huntington's disease pathology by delaying neuronal dysfunction. <i>Molecular Neurodegeneration</i> , <b>2011</b> , 6, 71	19	74
12	Increased PKA signaling disrupts recognition memory and spatial memory: role in Huntington's disease. <i>Human Molecular Genetics</i> , <b>2011</b> , 20, 4232-47	5.6	86
11	Thermogenic activation induces FGF21 expression and release in brown adipose tissue. <i>Journal of Biological Chemistry</i> , <b>2011</b> , 286, 12983-90	5.4	418
10	Peroxisome proliferator-activated receptor-gamma coactivator-1alpha controls transcription of the Sirt3 gene, an essential component of the thermogenic brown adipocyte phenotype. <i>Journal of Biological Chemistry</i> , <b>2011</b> , 286, 16958-66	5.4	145
9	BDNF regulation under GFAP promoter provides engineered astrocytes as a new approach for long-term protection in Huntington's disease. <i>Gene Therapy</i> , <b>2010</b> , 17, 1294-308	4	79
8	PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K/Akt pro-survival pathway in Huntington's disease striatum. <i>Cell Death and Differentiation</i> , <b>2010</b> , 17, 324-35	12.7	42
7	Age-dependent maintenance of motor control and corticostriatal innervation by death receptor 3. <i>Journal of Neuroscience</i> , <b>2010</b> , 30, 3782-92	6.6	18
6	Reduced calcineurin protein levels and activity in exon-1 mouse models of Huntington's disease: role in excitotoxicity. <i>Neurobiology of Disease</i> , <b>2009</b> , 36, 461-9	7.5	32
5	Cytotoxic effect of neuromyelitis optica antibody (NMO-IgG) to astrocytes: an in vitro study. Journal of Neuroimmunology, <b>2009</b> , 215, 31-5	3.5	81
4	Brain-derived neurotrophic factor modulates the severity of cognitive alterations induced by mutant huntingtin: involvement of phospholipaseCgamma activity and glutamate receptor expression. <i>Neuroscience</i> , <b>2009</b> , 158, 1234-50	3.9	91
3	Disruption of striatal glutamatergic transmission induced by mutant huntingtin involves remodeling of both postsynaptic density and NMDA receptor signaling. <i>Neurobiology of Disease</i> , <b>2008</b> , 29, 409-21	7.5	34
2	Dissociation between CA3-CA1 synaptic plasticity and associative learning in TgNTRK3 transgenic mice. <i>Journal of Neuroscience</i> , <b>2007</b> , 27, 2253-60	6.6	42

Translational profiling of mouse dopaminoceptive neurons reveals a role of PGE2 in dorsal striatum

1